|
| |
 |
| |
BREAST CANCER RESOURCE CENTER
|
| |
In women, breast cancer is the most common cancer and the second most common cause of death from cancer. Approximately 180,000 patients--both women and men--are diagnosed with breast cancer each year, and 40,000 people die each year from it. Breast cancer is the leading cause of death in women aged 44-50 years. The overall 5-year survival rate is 60%, but if caught early, the rate increases to 80%. |
| |
 |
| |
|
| |
Because of the high frequency of breast cancer and the esthetic and symbolic value invested in the breast, breast cancer has always been a source of severe distress to patients and their families. For the same reasons, breast cancer research has increased dramatically during the last 2 decades, resulting in extraordinary progress in our understanding of the disease and in new, more efficient and less toxic treatments.
| | |
|
| |
Of American women, 13% will be diagnosed with breast cancer in their lifetimes, making it the most common nonskin cancer among women. In addition, more than 3% will die from the disease. Breast cancer has surpassed lung cancer as the leading cause of cancer death in women worldwide, accounting for more than 400,000 deaths per year. In the United States, breast cancer trails only lung cancer as the second most common cause of cancer death in women. In 2002, more than 1.15 million new cases were diagnosed worldwide. More than 200,000 of these were in the United States alone. | | |
|
| |
In breast cancer, the general approach to evaluation has become formalized as triple assessment, involving clinical examination, imaging (usually mammography and/or ultrasound), and needle biopsy, but always perform this as part of a more general assessment beginning with clinical history.
| | |
|
| |
Excluding cancers of the skin, breast cancer is the most common type of cancer in women in the US, accounting for 1 of every 3 cancers diagnosed. With early detection, intervention and postoperative treatment breast cancer mortality has decreased. The use of mammography for screening has largely contributed to early detection; although its use has resulted in a minor increase in among in situ cancers detected. | | |
|
| |
|
| |
 |
| |
Murata Y, Ogawa Y, Yoshida S, Kubota K, Itoh S, Fukumoto M, Nishioka A, Moriki T, Maeda H, Tanaka Y. Utility of initial MRI for predicting extent of residual disease after neoadjuvant chemotherapy: Analysis of 70 breast cancer patients. Oncol Rep. 2004 Dec;12(6):1257-1262. |
| |
Kim JH, Lee SY, Oh SY, Han SI, Park HG, Yoo MA, Kang HS. Methyl jasmonate induces apoptosis through induction of Bax/Bcl-X(s) and activation of caspase-3 via ROS production in A549 cells.
Oncol Rep. 2004 Dec;12(6):1233-1238. |
| |
Hu X, Washington S, Verderame MF, Demers LM, Mauger D, Manni A. Biological activity of the S-adenosylmethionine decarboxylase inhibitor SAM486A in human breast cancer cells in vitro and in vivo.
Int J Oncol. 2004 Dec;25(6):1831-1838. |
| |
Louis M, Rosato RR, Brault L, Osbild S, Battaglia E, Yang XH, Grant S, Bagrel D. The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress.
Int J Oncol. 2004 Dec;25(6):1701-1711. |
| |
Nukatsuka M, Fujioka A, Nakagawa F, Oshimo H, Kitazato K, Uchida J, Sugimoto Y, Nagayama S, Fukushima M. Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
Int J Oncol. 2004 Dec;25(6):1531-1536. |
|
